Salvage local ablation therapy for radiation-recurrent prostate cancer

Salvage local ablation therapy for radiation-recurrent prostate cancer - Salvage ablation therapy for radiorecurrent prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035440

Enrollment

Registered

2019-01-07

Start date

2019-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

High-intensity focused ultrasound therapy once, 2-3 hours

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1)recurrent prostate cancer after radiation treatment 2)Clinical T1-2, N0 at initial treatment 3)Serum PSA value < 10ng/ml 4)Age over 20 years old

Exclusion criteria

Exclusion criteria: 1)Infecious disease at urinary tract and/or prostate 2)Metastatic disease

Design outcomes

Primary

Measure	Time frame
Serum PSA every 3 months	—

Secondary

Measure	Time frame
MRI prostate biopsy adverse event QOL questionnaire	—

Countries

Japan

Contacts

Public ContactAtsushi Ochiai

Kyoto prefectural University of Medicine Department of Urology

uro@koto.kpu-m.ac.jp075-251-5595

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026